These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3518596)

  • 1. Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner T; Drago J
    Anticancer Res; 1986; 6(2):309-14. PubMed ID: 3518596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial.
    Manni A; Santen RJ; Boucher A; Lipton A; Harvey H; Simmonds M; White D; Gordon R; Ronher T; Drago J
    Anticancer Res; 1985; 5(2):161-5. PubMed ID: 3888046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.
    Manni A; Bartholomew M; Caplan R; Boucher A; Santen R; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon R
    J Clin Oncol; 1988 Sep; 6(9):1456-66. PubMed ID: 3047336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; Gordon R; Rohner T; Drago J; Wettlaufer J
    J Steroid Biochem; 1987; 27(1-3):551-6. PubMed ID: 3695494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen priming and response to chemotherapy in advanced prostatic cancer.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Simmonds M; White-Hershey D; Gordon RA; Rohner TJ; Drago J
    J Urol; 1986 Dec; 136(6):1242-6. PubMed ID: 3534315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
    Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
    Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
    Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
    Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
    J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma.
    Hellerstedt B; Pienta KJ; Redman BG; Esper P; Dunn R; Fardig J; Olson K; Smith DC
    Cancer; 2003 Oct; 98(8):1603-10. PubMed ID: 14534875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.
    Pether M; Goldenberg SL; Bhagirath K; Gleave M
    Can J Urol; 2003 Apr; 10(2):1809-14. PubMed ID: 12773232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximal androgen blockade for advanced prostate cancer.
    Klotz L
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.
    English HF; Heitjan DF; Lancaster S; Santen RJ
    Cancer Res; 1991 Apr; 51(7):1760-5. PubMed ID: 2004359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice.
    Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF
    J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.